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Supplementary Figure 1.  
 
 
Schedule of drug administration and tumor measurements. Two groups of rats 
were investigated. For the control group, 3 rats were inoculated with tumor cells and 
received no treatment throughout the trial. For the IOR group, 5 rats were inoculated 
with tumor cells, treated twice with the CR regimen on day1 and day7, and then 
treated twice with IOR regimens on day14 and day24. Tumor sizes were recorded 
daily. Drug doses in serum after the first treatment were recorded for 9 time points.  
 
Supplementary Figure 2.  
See the attachment: supplementary figure 2 media.avi 
Dynamic feature of phenotypic response surfaces. For 4 drug combinations, 6 
PRS plots represent the drug-drug interactions. The normalized tumor size of rat 
IOR4 Vs. the 6 drug pairs are plotted during day 7-13. The PRS plots dynamically 
varied their shapes during days 7-13. The first frame of the video showed the PRSs 
before the 2
nd
 CR regimen was applied on day 7. The 2
nd
 CR regimen was 
subsequently applied at a time point after the first frame of the video on day 7. The 
PRS plots varied substantially as treatment time goes by.  
Supplementary Figure 3.  
 
 
Safety investigations of the individualized therapies. (a) Neutrophil quantification 
on day 21 and day 31. (b) Alanine aminotransferase (ALT) levels on day 21. (c) 
Comparison of ALT values against tumor size. Data are represented as mean ± 
standard deviation for each group.  
 
 
 
 
 
 
 
 
 
Supplementary Figure 4. Drug plasma concentration for each IOR subject 
during the first 64 hours after initial CR treatment. 
 
 
Supplementary Figure 5.  
 
Blood serum drug concentration for each IOR subject from day1 to day6. 
 
Supplementary Figure 6.  
 
 
Daily tumor sizes and serum drug doses. (a) adriamycin serum dose, (b) 
gemcitabine serum dose, (c) cisplatin serum dose, (d) herceptin serum dose and (e) 
tumor size (normalized to day 0) was recorded for each rat in IOR group. 15 data sets 
were generated from the 13 days (from day 1 to day 13 as indicated in the shaded 
area) of measurements with interpolation to generate individualized PRS for each rat, 
which was then applied to determine the individualized optimal regimen on day 14.  
 
 
 
 
 
Supplementary Figure 7.  
 
The IOR cohort was statistically examined using nonlinear least-squares 
regression.  
Matlab
©
 software was applied to examine the statistics using the fitnlm function. The 
results of the statistical analysis of rat IOR4 were plotted. (a) Fitted values from the 
PRS equation versus experimental observed values.  R
2
 equals to 0.983. The F test 
was used. (b) Residuals revealing differences between measured values and PRS 
values. (c) Cook’s distance indicated no outlier data points due to experimental 
errors. (d) Evaluation of whether any statistical transformation Yλ
 
was necessary for 
tumor size data in order to increase the PRS plotting efficiency. Importantly, λ is 
close to 1, indicating the tumor weight data was suitable to construct the PRS. R
2
 
equals to 0.983. The F test was used.  
 
 
Supplementary Table 1. Documented maximum tolerate doses for cisplatin, 
adriamycin, herceptin and gemcitabine  
 
Drugs  LD50  Reference 
to LD50  
Maximum tolerated dose 
[MTD]  
Reference 
to MTD  M.W. [g/mol]  
Cisplatin  11.0 mg/kg (IV)  (1)  6.00 mg/kg (weekly*3)  (2)  3.01 × 10
2 
 
Adriamycin  1.25 mg/kg (IV)  (3)  6.00 mg/kg  (4)  5.44 × 10
2 
 
Herceptin >5.11×10
3
 
mg/kg (Oral) 
(5) >94.0 mg/kg     (5) 1.46 × 10
5
 
Gemcitabine 500mg/kg (IV) (6) 120 mg/kg 
(every 3 days for 4 times) (7) 2.63 × 10
2
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Supplementary Table 2. (a) Tumor size, CR and IOR for each IOR rat. (b) Weights 
of both control and IOR groups   
(a) 
Rat 
 
 
 
Day 0 
 
Day 1 
CR 
Day  7 
CR 
Day 14 
IOR 
Day 24 
IOR 
IOR1 Tumor size[mm] 15.1 18.4 25.6 29.5 29.1 
 Weight[g] n/a 252 255 259 240 
 Adriamycin [mg] 0 0.378 0.382 0.207 0.192 
 Gemcitabine [mg] 0 7.56 7.64 11.655 10.800 
 Cisplatin [mg] 0 0.378 0.382 0.622 0.576 
 Herceptin [mg] 0 20.8 21.0 10.723 9.936 
IOR2 Tumor size[mm] 15.6 20.1 21.2 22.3 22.8 
 Weight[g] n/a 188 186 194 188 
 Adriamycin [mg] 0 0.282 0.279 0.601 0.583 
 Gemcitabine [mg] 0 5.64 5.58 2.910 2.820 
 Cisplatin [mg] 0 0.282 0.279 0.155 0.150 
 Herceptin [mg] 0 15.5 15.4 16.044 15.548 
IOR3 Tumor size[mm] 13.5 20.3 21.8 23.0 22.9 
 Weight[g] n/a 224 224 233 234 
 Adriamycin [mg] 0 0.335 0.335 0.350 0.351 
 Gemcitabine [mg] 0 6.71 6.71 6.990 7.020 
 Cisplatin [mg] 0 0.335 0.335 0.350 0.351 
 Herceptin [mg] 0 18.5 18.5 19.269 19.352 
IOR4 Tumor size[mm] 14.8 20.0 23.1 22.8 24.1 
 Weight[g] n/a 235 223 223 203 
 Adriamycin [mg] 0 0.353 0.334 0.691 0.629 
 Gemcitabine [mg] 0 7.05 6.68 3.345 3.045 
 Cisplatin [mg] 0 0.353 0.334 0.178 0.162 
 Herceptin [mg] 0 19.4 18.4 18.442 16.788 
IOR5 Tumor size[mm] 15.0 23.7 25.6 30.9 32.8 
 Weight[g] n/a 231 227 236 203 
 Adriamycin [mg] 0 0.346 0.340 0.732 0.629 
 Gemcitabine [mg] 0 6.92 6.80 3.540 3.045 
 Cisplatin [mg] 0 0.346 0.340 0.189 0.162 
 Herceptin [mg] 0 19.1 18.7 19.517 16.788 
 
 
 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 
 
 
 
 
Weight[g] Day1 Day7 Day14 Day24 
C1 207 216 222 228 
C2 195 194 204 213 
C3 211 210 225 227 
IOR1 252 255 259 240 
IOR2 188 186 194 188 
IOR3 224 224 233 234 
IOR4 235 223 223 203 
IOR5 231 227 236 203 
 
Supplementary Table 3. Optimized coefficients of 5 IOR rats at day14 
 
 
 
 
 
 
 
 xo x1 x2 x3 x4 y11 y22 y33 y44 z12 z13 z23 z14 z24 z34 
IOR 1 -1.13
×109 
-1.92
×108 
-1.33
×105 
1.82
×107 
-1.29
×104 
-2.76
×107 
1.56
×104 
-1.03
×106 6.37 
-2.52
×107 
2.71
×107 
4.47
×106 
1.02
×105 
-2.86
×103 
-1.45
×104 
IOR 2 -2.62
×109 
-4.07
×108 
3.19
×104 
1.24
×107 
1.89
×103 
-9.68
×106 
4.28
×104 
-6.18
×105 
1.41
×101 
-6.98
×107 
4.73
×107 
1.19
×107 
2.68
×105 
-7.42
×103 
-4.73
×104 
IOR 3 -1.45
×107 
-1.31
×107 
1.31
×104 
3.71
×104 
7.05
×101 
-2.89
×105 
9.17
×101 
8.48
×103 
2.29
×10-1 
-9.62
×104 
-8.89
×105 
2.48
×104 
1.51
×103 
-2.42
×101 
-1.98
×102 
IOR 4 -7.82
×108 
-1.33
×108 
1.08
×105 
7.65
×105 
2.63
×103 
-1.88
×107 
2.96
×103 
-5.33
×104 2.25 
-3.13
×106 
1.08
×107 
6.06
×105 
-1.19
×102 
-5.86
×102 
-1.57
×103 
IOR 5 -7.61
×108 
-1.61
×108 
1.45
×105 
3.63
×105 
3.84
×103 
-3.01
×106 
-5.38
×103 
-7.28
×103 6.87 
4.55
×106 
1.61
×107 
-1.21
×106 
-1.31
×104 
1.38
×103 
-7.96
×102 
 
Supplemental Table 4. IOR dose and MTD dose 
 IOR1 IOR2 IOR3 IOR4 IOR5 Ave 
Adriamycin 1.00 1.00 0.20 1.00 0.20 0.68 
Gemcitabine 0.80 1.00 0.20 1.00 0.20 0.64 
Cisplatin 1.06 0.20 1.05 0.20 1.04 0.70 
Herceptin 0.20 1.22 0.20 1.23 0.20 0.61 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 5. Data sets interpolated from these 13 day’s measurements 
were applied to construct the PRS of IOR1 and determine the optimal individualized 
regimen for IOR1 on day 14. 
 
Days after 
first 
treatment 
Tumor size 
of rat IOR 1 
normalized 
to day 0 
Accumulated plasma drug doses of rat IOR 1 
Adriamycin 
[ng/mL] 
Gemcitabine 
[ng/mL] 
Cisplatin 
[ng/mL] 
Herceptin 
[ng/mL] 
Day 1 1.22 5.62 × 10
1
 8.19 × 10
4
 1.53 × 10
3
 3.82 × 10
5
 
Day 2 1.74 5.63 × 10
1
 8.19 × 10
4
 1.58 × 10
3
 4.18 × 10
5
 
Day 3 1.70 5.64 × 10
1
 8.19 × 10
4
 1.61 × 10
3
 4.54 × 10
5
 
Day 4 1.76 5.64 × 10
1
 8.19 × 10
4
 1.61 × 10
3
 4.54 × 10
5
 
Day 5 1.73 5.64 × 10
1
 8.19 × 10
4
 1.61 × 10
3
 4.54 × 10
5
 
Day 6 1.70 5.64 × 10
1
 8.19 × 10
4
 1.61 × 10
3
 4.54 × 10
5
 
Day 7 1.70 1.12 × 10
2
 1.64 × 10
5
 3.14 × 10
3
 8.37 × 10
5
 
Day 8 1.80 1.12 × 10
2
 1.64 × 10
5
 3.19 × 10
3
 8.72× 10
5
 
Day 9 1.86 1.13 × 10
2
 1.64 × 10
5
 3.22 × 10
3
 9.08× 10
5
 
Day10 1.83 1.13 × 10
2
 1.64 × 10
5
 3.22 × 10
3
 9.08× 10
5
 
Day11 1.97 1.13 × 10
2
 1.64 × 10
5
 3.22 × 10
3
 9.08× 10
5
 
Day12 1.97 1.13 × 10
2
 1.64 × 10
5
 3.22 × 10
3
 9.08× 10
5
 
Day13 1.96 1.13 × 10
2
 1.64 × 10
5
 3.22 × 10
3
 9.08× 10
5
 
 
